(maximum stimulation Ϸ50% of wild type). This G protein-independent activation of mitogen-activated protein kinase is abolished by depletion of cellular ␤-arrestin 2 but is unaffected by the PKC inhibitor Ro-31-8425. In parallel, stimulation of the wild-type angiotensin type 1A receptor with Ang II robustly stimulates ERK1͞2 activation with Ϸ60% of the response blocked by the PKC inhibitor (G protein dependent) and the rest of the response blocked by depletion of cellular ␤-arrestin 2 by small interfering RNA (␤-arrestin dependent). These findings imply the existence of independent G protein-and ␤-arrestin 2-mediated pathways leading to ERK1͞2 activation and the existence of distinct ''active'' conformations of a seven-membrane-spanning receptor coupled to each.
S
ignaling by seven-membrane-spanning receptors (7MSRs), such as the angiotensin type 1A (AT 1A ) receptor, is conventionally ascribed to activation of heterotrimeric G proteins. However, over the past several years an increasing number of examples have been described in which such receptors signal in situations in which G protein activation appears to be minimal or absent (reviewed in ref. 1). In particular, several different angiotensin receptor mutants and angiotensin peptides, which are not able to activate G proteins, have been shown to activate the mitogen-activated protein kinase (MAPK) extracellular signal-regulated kinases 1 and 2 (ERK1͞2) (2) (3) (4) . Nonetheless, the mechanisms mediating such G protein-independent signaling have remained unknown.
One candidate for a molecule that might mediate such signaling is ␤-arrestin. Originally discovered in connection with their ability, together with G protein-coupled receptor kinases, to desensitize activated 7MSRs, ␤-arrestin 1 and 2 have been found recently to act as adaptors in clathrin-mediated endocytosis and as scaffolds for signaling pathways, such as those leading to activation of MAPKs (5-7). ␤-Arrestin 2 has been shown to form complexes with the AT 1A , NK1 (neurokinin 1), and V2 (vasopressin 2) receptors, which scaffold and facilitate activation of the ERK cascade while targeting the activated ERK to endocytic vesicles in the cytoplasm (8) (9) (10) . Whether the ␤-arrestin acts distal to or independent of G proteins in such signaling is not known. Accordingly, we set out in the present studies to determine the relationship of G proteins and ␤-arrestins in ERK activation by the AT 1A receptor. ]Ang II (Sar, sarcosine) was synthesized in the Cleveland Clinic core synthesis facility. Phorbol 12-myristate 13-acetate (PMA) and Ro-31-8425 were purchased from Calbiochem. Chemically synthesized, double-stranded small interfering RNAs (siRNAs) corresponding to human ␤-arrestin 2 (bases 148-168 from start codon; target sequence 5Ј-AAGGACCGCAAAGUGUUU-GUG-3Ј) and a nonsilencing control (sequence 5Ј-AAGUG-GACCCUGUAGAUGGCG-3Ј) were purchased from Xeragon (Germantown, MD) in deprotected and desalted form. GeneSilencer transfection reagents were obtained from Gene Therapy Systems (San Diego). All other reagents were purchased from Sigma. The pCDNA3.1 expression plasmid encoding hemagglutinin (HA) epitope-tagged AT 1A receptor (pcDNA3.1-HA-AT 1A R) was provided by M. G. Caron (Duke University). The pCDNA3.1-DRY͞AAY mutant AT 1A receptor construct was described (11) . GFP-tagged ␤-arrestin 2 (␤-arrestin 2-GFP) was made by cloning rat ␤-arrestin 2 cDNA in frame in pEGFPN1 (Clontech) between the HindIII and ApaI sites.
Materials and Methods
Cell Culture and DNA Transfection. Human embryonic kidney (HEK)-293 cells were grown in Eagle's minimum essential medium (MEM) with Earle's salts supplemented with 10% (vol͞vol) FBS and a 1:100 dilution of a penicillin͞streptomycin mixture (Sigma). Cells were transiently transfected in 10-cm dishes with 2 g of pcDNA3.1-HA-AT 1A R or pcDNA3.1-DRY͞ AAY by using FuGENE 6 reagent (Roche Molecular Biochemicals) according to the manufacturer's instructions.
Inositol Phosphate (IP) Determination. Transiently transfected HEK-293 cells in 10-cm dishes were plated onto poly-D-lysinecoated 12-well plates (BD Biosciences Labware). To assay for IP production, cells were incubated overnight at 37°C in labeling medium [1 Ci (1 Ci ϭ 37 GBq) of myo-[ cell-surface receptor expression (13) . Total protein was determined by the Bradford reaction and was used to standardize AT 1A receptor expression levels. The receptor expression levels for wild-type and DRY͞AAY (Asp-Arg-Tyr͞Ala-Ala-Tyr) mutant AT 1A receptor are 1. [ 35 S]GTP␥S Binding Assay. Transiently transfected HEK-293 cells in 10-cm dishes were washed twice in PBS, collected in ice-cold homogenization buffer (20 mM Tris⅐HCl, pH 7.4͞100 mM NaCl͞1 mM EDTA͞10 M GDP͞1 mM PMSF͞protease inhibitors) and disrupted with a Dounce homogenizer. Crude membranes were prepared by centrifugation at 30,000 ϫ g for 30 min at 4°C. Membranes were resuspended in assay buffer (50 mM Tris⅐HCl, pH 7.4͞100 mM NaCl͞5 mM MgCl 2 ͞1 mM EDTA͞1 mM DTT͞10 M GDP). Membranes (15 g of protein per assay tube) were incubated in 100 pM [ 35 S]GTP␥S in the presence or absence of agonist for 1 h at 30°C. Binding was terminated by addition of 1 ml of 100 M GDP͞GTP mixture and rapid filtration over GF͞B (glass fiber) filters. Filters were washed five times with ice-cold water and dried, and their radioactivity was measured with a liquid scintillation counter (Packard).
siRNA Transfection. HEK-293 cells were transfected simultaneously with 2 g of pcDNA3.1-HA-AT 1A R or pcDNA3.1-DRY͞AAY and 20 g of ␤-arrestin 2 siRNA or control siRNA as described (14) . ]Ang II for 30 min at 37°C, fixed with PBS containing 5% formaldehyde for 30 min, and washed three times with PBS. Confocal microscopy was performed at ϫ100 magnification with a Zeiss LSM-510 laserscanning microscope. Images were collected by using 488-nm excitation and a 515-to 540-nm emission filter.
Preparation of Cellular Extracts and Immunoblotting. Cells were solubilized in a lysis buffer [50 mM Hepes, pH 7.5͞0.5% Nonidet P-40͞250 mM NaCl͞2 mM EDTA͞10% (vol͞vol) glycerol͞1 mM sodium orthovanadate͞1 mM sodium fluoride͞1 mM phenylmethylsulfonyl fluoride͞5 g/ml leupeptin͞5 g/ml aprotinin͞1 g/ml pepstatin A͞100 M benzamidine] and then clarified by centrifugation for 10 min at 21,000 ϫ g. Equal amounts of supernatant proteins were separated on 10% Tris⅐glycine polyacrylamide gels (Invitrogen) and transferred to nitrocellulose membranes for immunoblotting. Phosphorylated ERK1͞2, total ERK1͞2, and ␤-arrestin 2 were detected by immunoblotting with an anti-phospho-p44͞42 MAPK antibody (1:3,000; Cell Signaling Technology, Beverly, MA), an anti-MAPK1͞2 (1:10,000; Upstate Biotechnology, Lake Placid, NY), and a rabbit polyclonal anti-␤-arrestin 2 antibody (A2CT) (1:5,000), respectively. Chemiluminescent detection was performed by using SuperSignal West Pico reagent (Pierce), and phosphorylated ERK1͞2 immunoblots were quantified by densitometry with a Fluor-S MultiImager (Bio-Rad).
Results and Discussion
The highly conserved E͞DRY (Glu͞Asp-Arg-Tyr) motif in the second intracellular loop of 7MSRs is important for G protein coupling. The conserved Arg residue in the rhodopsin E͞DRY motif has been shown to interact directly with the G protein to catalyze GDP release (15) , and its mutation causes impaired signal transduction in many receptors (16, 17) . Recently it was reported that the AT 1A receptor mutant DRY͞AAY (Fig. 1A) is severely impaired in G␣ q͞11 -coupling in COS-7 cells (11). When we transiently expressed this receptor mutant in HEK-293 cells, no detectable inositol 1,4,5-trisphosphate accumulation was observed ( Fig. 2A) , confirming that this mutant receptor lacks functional coupling with G␣ q͞11 .
Similarly, selected synthetic analogues of Ang II have been described that can support AT 1A receptor internalization without activating IP production through G␣ q͞11 (Fig. 1B) (3) . The AT 1A receptor has been reported to be able to couple to additional G proteins, such as G i , in some cell lines (18 DRY͞AAY mutant receptor-transfected cells (Fig. 2B) . Consistent with this finding, mutation in the Arg residue of E͞DRY motif in the N-formyl peptide receptor has also been shown to abolish G protein coupling (19 ]Ang IIbound AT 1A receptors, we used confocal microscopy to monitor translocation of ␤-arrestin 2-GFP to receptors on agonist treatment. When ␤-arrestin 2-GFP was coexpressed with the wildtype AT 1A receptor or the DRY͞AAY mutant receptor, ␤-arrestin 2-GFP was distributed uniformly in the cytoplasm of cells (Fig. 3A) . As shown previously, Ang II induced translocation of ␤-arrestin 2-GFP to endocytic vesicles in cells expressing AT 1A receptors (Fig. 3B) because of a stable interaction between ␤-arrestin 2-GFP and internalized AT 1A receptors (20) . Ang II-induced translocation of ␤-arrestin 2-GFP to endocytic vesicles was also detected in DRY͞AAY mutant receptortransfected cells, suggesting that ␤-arrestin 2 interacts with the DRY͞AAY mutant receptor and mediates its internalization on agonist treatment (Fig. 3C) ]Ang II or the DRY͞AAY mutant receptor with Ang II, despite their inability to activate G proteins, led to robust ERK1͞2 activation, which was Ϸ50% of that for the wild-type receptor stimulated by Ang II (Fig. 4A) to 7MSR in an agonist-dependent manner. In the case of the AT 1A receptor, ␤-arrestin 2-bound ERK1͞2 has been shown to undergo Ang II-stimulated activation and to localize with the AT 1A receptor in endosomal vesicles (8, 9) . To assess the importance of ␤-arrestin 2 in mediating the G proteinindependent activation of ERK1͞2 documented above, we used the RNA interference technique to down-regulate the expression of endogenous ␤-arrestin 2 and examined (Fig. 4 D and E) or by the DRY͞AAY mutant receptor stimulated by Ang II (Fig. 4 F and  G) . This finding indicates that the G protein-independent activation of ERK1͞2 mediated by [Sar ]Ang II-bound AT 1A receptors or Ang II-bound DRY͞AAY mutant receptors is completely dependent on ␤-arrestin 2. Because our ␤-arrestin 2 siRNA did not lead to a decrease in ␤-arrestin 1 expression levels (data not shown), these results also suggest that ␤-arrestin 2, not ␤-arrestin 1, is the major form of ␤-arrestin mediating Ang II-induced G protein-independent ERK1͞2 activation.
Because G protein-mediated actions of Ang II are typically transduced by G q (leading to generation of IP and diacylglycerol and activation of PKC), and because PKC has been shown previously to mediate the Ang II-induced ERK1͞2 activation in some physiological target tissues (25), we tested the effects of the PKC inhibitor Ro-31-8425 on ERK1͞2 activation (Fig. 5 A and  B) . Activation of ERK1͞2 by wild-type receptor stimulated with Ang II was inhibited Ϸ60% by the PKC inhibitor (Fig. 5A, lanes  3 and 4, Fig. 5B ), and the residual activity was virtually eliminated by ␤-arrestin 2 RNA interference (Fig. 5A, lanes 4 and 10,  Fig. 5B (Fig.  5A, lanes 5 and 6) . As expected, the PKC inhibitor blocked Erk1͞2 activation by PMA completely (Fig. 5A, lanes 15 and 16) .
Our results demonstrate the existence of two parallel independent pathways by which ERK can be activated by the AT 1A receptor. One pathway is G protein-dependent and involves PKC activation, the other is G protein-independent and is mediated by ␤-arrestin 2. These findings document that ␤-arrestin 2 can act as a signal transducer entirely independent of G proteins. However, our results in no way rule out the possibility that under other circumstances G proteins and ␤-arrestin 2 might act sequentially. One can imagine several scenarios in which such sequential rather than parallel activation of the two pathways might occur. For example, in cases where ␤-arrestin 2 recruitment is triggered by GRK2͞3 (G protein-coupled receptor kinases 2 and 3)-mediated receptor phosphorylation, the role of free G␤␥ in this process would require prior G protein activation (26, 27) . Alternatively, sequential signaling might result when initial rapid G protein activation of ERK1͞2 is subsequently terminated (''desensitized'') by ␤-arrestin 2, which concurrently initiates the ␤-arrestin 2-dependent phase of ERK1͞2 activation.
It seems likely that ERK1͞2 activation mediated by ␤-arrestin 2 will lead to physiological consequences significantly different from those achieved by G protein activation. ERK1͞2 activated by G proteins generally accumulates in the nucleus, where it phosphorylates and activates various transcription factors (28) . In contrast, ERK1͞2 activated by ␤-arrestin is excluded from the nucleus and is confined to a cytoplasmic compartment (8) where it presumably phosphorylates a distinct set of effectors. Consistent with our findings, ERK1͞2 activated by an AT 1A mutant receptor uncoupled from G proteins has been shown to localize to the cytoplasm and to be unable to induce activation of Elk1 (2) . Similarly, stimulation of the DRY͞AAY mutant receptor with Ang II does not induce significant Elk1 activation (11) .
An important implication of this work is that the receptor can exist in more than one ''active'' conformation. Thus, the receptor conformation induced by [Sar ]Ang II in the wild-type receptor, or by wild-type Ang II in the DRY͞AAY mutant receptor, which is competent to activate ERK1͞2 via ␤-arrestin 2, is not able to activate G proteins. Multiple active conformations of 7MSRs have been suggested previously, but have been difficult to document (29, 30) . The clear demonstration here of such functionally distinct active conformations, potentially coupled to distinct signaling pathways, gives credibility and impetus 
